Skip to main content
Top
Published in: Annals of General Psychiatry 1/2012

Open Access 01-12-2012 | Primary research

Body composition in patients with schizophrenia: Comparison with healthy controls

Authors: Norio Sugawara, Norio Yasui-Furukori, Shoko Tsuchimine, Akira Fujii, Yasushi Sato, Manabu Saito, Masashi Matsuzaka, Ippei Takahashi, Sunao Kaneko

Published in: Annals of General Psychiatry | Issue 1/2012

Login to get access

Abstract

Background

Recently, a relationship between obesity and schizophrenia has been reported. Although fat- mass and fat free mass have been shown to be more predictive of health risk than body mass index, there are limited findings about body composition among patients suffering from schizophrenia. The aim of this study is to compare the body composition of schizophrenia patients with that of healthy subjects in Japan.

Methods

We recruited patients (n = 204), aged 41.3 ± 13.8 (mean ± SD) years old with the DSM-IV diagnosis of schizophrenia who were admitted to psychiatric hospital using a cross-sectional design. Subjects' anthropometric measurements including weight, height, body mass index (BMI), and medications were also collected. Body fat, percent (%) body fat, fat- free mass, muscle mass, and body water were measured using the bioelectrical impedance analysis (BIA) method. Comparative analysis was performed with schizophrenic subjects and 204 healthy control individuals.

Results

In a multiple regression model with age, body mass index, and dose in chlorpromazine equivalents, schizophrenia was a significantly linked with more body fat, higher % body fat, lower fat- free mass, lower muscle mass, and lower body water among males. In females, schizophrenia had a significant association with lower % body fat, higher fat- free mass, higher muscle mass, and higher body water.

Conclusions

Our data demonstrate gender differences with regard to changes in body composition in association with schizophrenia. These results indicate that intervention programs designed to fight obesity among schizophrenic patients should be individualized according to gender.
Literature
1.
go back to reference Susce MT, Villanueva N, Diaz FJ, de Leon J: Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry. 2005, 66: 167-173. 10.4088/JCP.v66n0203.CrossRefPubMed Susce MT, Villanueva N, Diaz FJ, de Leon J: Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry. 2005, 66: 167-173. 10.4088/JCP.v66n0203.CrossRefPubMed
2.
go back to reference Dickerson FB, Brown CH, Kreyenbuhl JA, Fang L, Goldberg RW, Wohlheiter K, Dixon LB: Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006, 113: 306-313. 10.1111/j.1600-0447.2005.00637.x.CrossRefPubMed Dickerson FB, Brown CH, Kreyenbuhl JA, Fang L, Goldberg RW, Wohlheiter K, Dixon LB: Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006, 113: 306-313. 10.1111/j.1600-0447.2005.00637.x.CrossRefPubMed
3.
go back to reference Martin RL, Cloninger CR, Guze SB, Clayton PJ: Mortality in a follow-up of 500 psychiatric outpatients, I. Total mortality. Arch Gen Psychiatry. 1985, 42: 47-54. 10.1001/archpsyc.1985.01790240049005.CrossRefPubMed Martin RL, Cloninger CR, Guze SB, Clayton PJ: Mortality in a follow-up of 500 psychiatric outpatients, I. Total mortality. Arch Gen Psychiatry. 1985, 42: 47-54. 10.1001/archpsyc.1985.01790240049005.CrossRefPubMed
5.
go back to reference Leucht S, Burkard T, Henderson J, Maj M, Sartorius N: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007, 116: 317-333. 10.1111/j.1600-0447.2007.01095.x.CrossRefPubMed Leucht S, Burkard T, Henderson J, Maj M, Sartorius N: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007, 116: 317-333. 10.1111/j.1600-0447.2007.01095.x.CrossRefPubMed
6.
go back to reference De Hert M, Peuskens B, van Winkel R, Kalnicka D, Hanssens L, Van Eyck D, Wyckaert S, Peuskens J: Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res. 2006, 88: 222-226. 10.1016/j.schres.2006.07.025.CrossRefPubMed De Hert M, Peuskens B, van Winkel R, Kalnicka D, Hanssens L, Van Eyck D, Wyckaert S, Peuskens J: Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res. 2006, 88: 222-226. 10.1016/j.schres.2006.07.025.CrossRefPubMed
7.
go back to reference Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003, 54: 565-567. 10.1176/appi.ps.54.4.565.CrossRefPubMed Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003, 54: 565-567. 10.1176/appi.ps.54.4.565.CrossRefPubMed
8.
go back to reference Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2003, 66: 51-57.CrossRef Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2003, 66: 51-57.CrossRef
9.
go back to reference Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA: The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry. 2009, 31: 1-7. 10.1016/j.genhosppsych.2008.09.012.PubMedCentralCrossRefPubMed Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA: The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry. 2009, 31: 1-7. 10.1016/j.genhosppsych.2008.09.012.PubMedCentralCrossRefPubMed
10.
go back to reference Bigaard J, Frederiksen K, Tjønneland A, Thomsen BL, Overvad K, Heitmann BL, Sørensen TI: Body fat and fat-free mass and all-cause mortality. Obes Res. 2004, 12: 1042-1049. 10.1038/oby.2004.131.CrossRefPubMed Bigaard J, Frederiksen K, Tjønneland A, Thomsen BL, Overvad K, Heitmann BL, Sørensen TI: Body fat and fat-free mass and all-cause mortality. Obes Res. 2004, 12: 1042-1049. 10.1038/oby.2004.131.CrossRefPubMed
11.
go back to reference Ellis KJ: Human body composition: in vivo methods. Physiol Rev. 2000, 80: 649-680.PubMed Ellis KJ: Human body composition: in vivo methods. Physiol Rev. 2000, 80: 649-680.PubMed
12.
go back to reference Kitano T, Kitano N, Inomoto T, Futatsuka M: Evaluation of body composition using dual-energy X-ray absorptiometry, skinfold thickness and bioelectrical impedance analysis in Japanese female college students. J Nutr Sci Vitaminol. 2001, 47: 122-125. 10.3177/jnsv.47.122.CrossRefPubMed Kitano T, Kitano N, Inomoto T, Futatsuka M: Evaluation of body composition using dual-energy X-ray absorptiometry, skinfold thickness and bioelectrical impedance analysis in Japanese female college students. J Nutr Sci Vitaminol. 2001, 47: 122-125. 10.3177/jnsv.47.122.CrossRefPubMed
13.
go back to reference Boneva-Asiova Z, Boyanov MA: Body composition analysis by leg-to-leg bioelectrical impedance and dual-energy X-ray absorptiometry in non-obese and obese individuals. Diabetes Obes Metab. 2008, 10: 1012-1018. 10.1111/j.1463-1326.2008.00851.x.CrossRefPubMed Boneva-Asiova Z, Boyanov MA: Body composition analysis by leg-to-leg bioelectrical impedance and dual-energy X-ray absorptiometry in non-obese and obese individuals. Diabetes Obes Metab. 2008, 10: 1012-1018. 10.1111/j.1463-1326.2008.00851.x.CrossRefPubMed
14.
go back to reference Inagaki A, Inada T: Dose equivalence of novel antipsychotics. Part 5. Jpn J Clin Psychopharm. 2008, 11: 887-890. (Japanese) Inagaki A, Inada T: Dose equivalence of novel antipsychotics. Part 5. Jpn J Clin Psychopharm. 2008, 11: 887-890. (Japanese)
15.
go back to reference Tanita Corp.2005: Tanita MC-190 User's Guide. 3-8. (Japanese) Tanita Corp.2005: Tanita MC-190 User's Guide. 3-8. (Japanese)
16.
go back to reference Nilsson BM, Forslund AH, Olsson RM, Hambraeus L, Wiesel FA: Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr Scand. 2006, 114: 27-35. 10.1111/j.1600-0447.2005.00700.x.CrossRefPubMed Nilsson BM, Forslund AH, Olsson RM, Hambraeus L, Wiesel FA: Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr Scand. 2006, 114: 27-35. 10.1111/j.1600-0447.2005.00700.x.CrossRefPubMed
17.
go back to reference Satoh M, Sakuda H, Kobayashi T, Kataoka T, Nakao F, Turale S: Comparison of the body fluid levels in healthy individuals and those with schizophrenia in Japan: using the bioelectrical impedance method. Nurs Health Sci. 2007, 9: 177-184. 10.1111/j.1442-2018.2007.00322.x.CrossRefPubMed Satoh M, Sakuda H, Kobayashi T, Kataoka T, Nakao F, Turale S: Comparison of the body fluid levels in healthy individuals and those with schizophrenia in Japan: using the bioelectrical impedance method. Nurs Health Sci. 2007, 9: 177-184. 10.1111/j.1442-2018.2007.00322.x.CrossRefPubMed
18.
go back to reference Saarni SE, Saarni SI, Fogelholm M, Heliövaara M, Perälä J, Suvisaari J, Lönnqvist J: Body composition in psychotic disorders: a general population survey. Psychol Med. 2009, 39: 801-810. 10.1017/S0033291708004194.CrossRefPubMed Saarni SE, Saarni SI, Fogelholm M, Heliövaara M, Perälä J, Suvisaari J, Lönnqvist J: Body composition in psychotic disorders: a general population survey. Psychol Med. 2009, 39: 801-810. 10.1017/S0033291708004194.CrossRefPubMed
19.
go back to reference Roubenoff R: Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci. 2003, 58: 1012-1017. 10.1093/gerona/58.11.M1012.CrossRefPubMed Roubenoff R: Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci. 2003, 58: 1012-1017. 10.1093/gerona/58.11.M1012.CrossRefPubMed
20.
go back to reference Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006, 354: 2552-2563. 10.1056/NEJMoa054862.CrossRefPubMed Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006, 354: 2552-2563. 10.1056/NEJMoa054862.CrossRefPubMed
21.
go back to reference Ryan MC, Thakore JH: Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002, 71: 239-257. 10.1016/S0024-3205(02)01646-6.CrossRefPubMed Ryan MC, Thakore JH: Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002, 71: 239-257. 10.1016/S0024-3205(02)01646-6.CrossRefPubMed
22.
go back to reference Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002, 26: 137-141. 10.1038/sj.ijo.0801840.CrossRefPubMed Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002, 26: 137-141. 10.1038/sj.ijo.0801840.CrossRefPubMed
23.
go back to reference Björntorp P, Rosmond R: Obesity and cortisol. Nutrition. 2000, 16: 924-936. 10.1016/S0899-9007(00)00422-6.CrossRefPubMed Björntorp P, Rosmond R: Obesity and cortisol. Nutrition. 2000, 16: 924-936. 10.1016/S0899-9007(00)00422-6.CrossRefPubMed
24.
go back to reference Kaneda Y, Fujii A, Ohmori T: The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry. 2002, 26: 935-938. 10.1016/S0278-5846(02)00208-7.CrossRefPubMed Kaneda Y, Fujii A, Ohmori T: The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry. 2002, 26: 935-938. 10.1016/S0278-5846(02)00208-7.CrossRefPubMed
25.
go back to reference Louet JF, LeMay C, Mauvais-Jarvis F: Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep. 2004, 6: 180-185. 10.1007/s11883-004-0030-9.CrossRefPubMed Louet JF, LeMay C, Mauvais-Jarvis F: Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep. 2004, 6: 180-185. 10.1007/s11883-004-0030-9.CrossRefPubMed
26.
go back to reference D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS: Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem. 2005, 280: 35983-35991. 10.1074/jbc.M507339200.CrossRefPubMed D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS: Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem. 2005, 280: 35983-35991. 10.1074/jbc.M507339200.CrossRefPubMed
27.
go back to reference Tiidus PM: Estrogen and gender effects on muscle damage, inflammation, and oxidative stress. Can J Appl Physiol. 2000, 25: 274-287. 10.1139/h00-022.CrossRefPubMed Tiidus PM: Estrogen and gender effects on muscle damage, inflammation, and oxidative stress. Can J Appl Physiol. 2000, 25: 274-287. 10.1139/h00-022.CrossRefPubMed
28.
go back to reference Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009, 302: 1765-1773. 10.1001/jama.2009.1549.PubMedCentralCrossRefPubMed Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009, 302: 1765-1773. 10.1001/jama.2009.1549.PubMedCentralCrossRefPubMed
29.
go back to reference Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M: Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004, 65: 471-477.CrossRefPubMed Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M: Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004, 65: 471-477.CrossRefPubMed
30.
go back to reference Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A: Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007, 41: 980-989. 10.1080/00048670701689428.CrossRefPubMed Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A: Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007, 41: 980-989. 10.1080/00048670701689428.CrossRefPubMed
Metadata
Title
Body composition in patients with schizophrenia: Comparison with healthy controls
Authors
Norio Sugawara
Norio Yasui-Furukori
Shoko Tsuchimine
Akira Fujii
Yasushi Sato
Manabu Saito
Masashi Matsuzaka
Ippei Takahashi
Sunao Kaneko
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2012
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/1744-859X-11-11

Other articles of this Issue 1/2012

Annals of General Psychiatry 1/2012 Go to the issue